Nirsevimab is effective for protecting infants against respiratory syncytial virus (RSV)-associated lower respiratory tract ...

Vaccinating pregnant women against respiratory syncytial virus (RSV) is linked to a 72% drop in newborns being hospitalized ...

Despite strong clinical data, RSV immunization rates among pregnant women and older adults remain worryingly low, ...

RESPIRATORY SYNCYTIAL VIRUS (RSV) is a pneumovirus frequently associated with respiratory illnesses. 1-3 While RSV has been known to cause serious complications in infants and young children, it ...

RSV primarily affects children and older adults, and can lead to severe illness or death. Severe illness from respiratory syncytial virus (RSV) can be prevented by administration of prophylactic ...

Respiratory syncytial virus (RSV) poses a significant, often overlooked, risk for serious cardiovascular complications in ...

The risk for respiratory syncytial virus-related hospitalizations is elevated in children with chronic medical conditions ...

announced top-line Abrysvo vaccine efficacy and safety data for respiratory syncytial virus (RSV) in adults 60 years of age and older following a second season in the Northern and Southern ...

Respiratory syncytial virus (RSV) is a major cause of respiratory infections, particularly in infants, children under 5 years, and older adults. Its rapid spread makes RSV a serious public health ...

Respiratory syncytial virus (RSV) is a well-known cause of infections in children, but it's understudied in older individuals ...

AI has become a critical tool in diagnosing and managing viral infections such as influenza, respiratory syncytial virus (RSV ...

Discover the latest insights in the "Respiratory Syncytial Virus (RSV) Infections - Global Clinical Trials Review, 2025." This comprehensive report details RSV clinical trial data, including trial ...